APA (7th ed.) Citation

von Tresckow, J., Cramer, P., Robrecht, S., Langerbeins, P., Fink, A., Al-Sawaf, O., . . . Hallek, M. (2022). Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL). Leukemia, 36(8), 2125. https://doi.org/10.1038/s41375-022-01629-7

Chicago Style (17th ed.) Citation

von Tresckow, Julia, et al. "Sequential Treatment with Bendamustine, Obinutuzumab (GA101) and Ibrutinib in Chronic Lymphocytic Leukemia (CLL)." Leukemia 36, no. 8 (2022): 2125. https://doi.org/10.1038/s41375-022-01629-7.

MLA (9th ed.) Citation

von Tresckow, Julia, et al. "Sequential Treatment with Bendamustine, Obinutuzumab (GA101) and Ibrutinib in Chronic Lymphocytic Leukemia (CLL)." Leukemia, vol. 36, no. 8, 2022, p. 2125, https://doi.org/10.1038/s41375-022-01629-7.